Novo Nordisk A/S (NYSE:NVO) Stock Price Up 0%

Novo Nordisk A/S (NYSE:NVO) rose 0% during mid-day trading on Friday . The stock traded as high as $127.06 and last traded at $125.42. Approximately 1,360,576 shares changed hands during trading, a decline of 73% from the average daily volume of 4,960,142 shares. The stock had previously closed at $125.40.

Wall Street Analysts Forecast Growth

NVO has been the topic of several analyst reports. UBS Group initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research report on Friday. They set an “outperform” rating and a $163.00 price target on the stock. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday, April 1st. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Stock Performance

The stock has a market capitalization of $558.74 billion, a price-to-earnings ratio of 46.03, a P/E/G ratio of 2.09 and a beta of 0.41. The company’s fifty day simple moving average is $125.93 and its 200 day simple moving average is $109.74. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The business had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. On average, equities research analysts expect that Novo Nordisk A/S will post 3.33 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were paid a $0.664 dividend. The ex-dividend date of this dividend was Friday, March 22nd. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio is 49.17%.

Hedge Funds Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently modified their holdings of the business. Inspirion Wealth Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the first quarter valued at about $253,000. Fermata Advisors LLC acquired a new stake in Novo Nordisk A/S during the first quarter worth about $300,000. Annex Advisory Services LLC acquired a new stake in Novo Nordisk A/S during the first quarter worth about $1,142,000. Divergent Planning LLC acquired a new stake in Novo Nordisk A/S during the first quarter worth about $281,000. Finally, Capital Advisors Wealth Management LLC grew its stake in Novo Nordisk A/S by 8.0% during the first quarter. Capital Advisors Wealth Management LLC now owns 9,691 shares of the company’s stock worth $1,244,000 after buying an additional 720 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.